Eargo, Inc. Stock: price and directors' dealings · United States · SEC (Form 4) Follow the Eargo, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Eargo, Inc. has published 56 reports. The latest transaction was filed on 20 February 2024 (Disposition). Among the most active insiders: Brownie William. All data is free.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
Generate AI analysis AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 20 February 2024
All Executives56 Thresholds0 Prospectus0 Other0
Declarations 56 total
● CFO & CAO · Executives · 16 Feb 2024
32 shares Common Stock SEC:0000950103-24-002447:0
● Director · Executives · 16 Feb 2024
25,463 shares Common Stock SEC:0000950103-24-002453:0
● Interim CEO & COO · Executives · 16 Feb 2024
38 shares Common Stock SEC:0000950103-24-002455:0
● Chief Accounting Officer · Executives · 29 Nov 2023
1,029 shares @ US$2.59 60.1% of flow Common Stock SEC:0001209191-23-056967:0
● Chief Financial Officer · Executives · 20 Nov 2023
33 shares @ US$2.60 0.1% of flow Common Stock SEC:0001209191-23-056456:0
● Chief Accounting Officer · Executives · 17 Nov 2023
3 shares @ US$2.56 0.2% of flow Common Stock SEC:0001209191-23-055742:0
● Interim CEO & COO · Executives · 17 Nov 2023
14 shares @ US$2.56 0.0% of flow Common Stock SEC:0001209191-23-055738:0
● Chief Financial Officer · Executives · 15 Nov 2023
2,842 shares @ US$2.55 7.4% of flow Common Stock SEC:0001209191-23-055740:0
● Interim CEO & COO · Executives · 13 Nov 2023
6,114 shares @ US$2.552 14.4% of flow Common Stock SEC:0001209191-23-055334:0
▼ Chief Accounting Officer · Executives · 17 Aug 2023
3 shares @ US$3.23 0.2% of flow Common Stock SEC:0001209191-23-046240:0
▼ Interim CEO & COO · Executives · 17 Aug 2023
14 shares @ US$3.23 0.0% of flow Common Stock SEC:0001209191-23-046246:0
▼ Chief Financial Officer · Executives · 17 Aug 2023
19 shares @ US$3.2353 0.1% of flow Common Stock SEC:0001209191-23-046243:0
▼ Chief Financial Officer · Executives · 17 May 2023
19 shares @ US$4.6901 0.1% of flow Common Stock SEC:0001209191-23-030591:0
▼ Chief Accounting Officer · Executives · 17 May 2023
3 shares @ US$4.6901 0.3% of flow Common Stock SEC:0001209191-23-030590:0
▼ President and CEO · Executives · 17 May 2023
58 shares @ US$4.6901 0.2% of flow Common Stock SEC:0001209191-23-030605:0
▼ Chief Operating Officer · Executives · 17 May 2023
14 shares @ US$4.6901 0.1% of flow Common Stock SEC:0001209191-23-030604:0
▼ President and CEO · Executives · 17 Feb 2023
64 shares @ US$7.3701 0.4% of flow Common Stock SEC:0001209191-23-011607:0
▼ Chief Operating Officer · Executives · 17 Feb 2023
15 shares @ US$7.3701 0.1% of flow Common Stock SEC:0001209191-23-011611:0
▼ Chief Financial Officer · Executives · 17 Feb 2023
21 shares @ US$7.3701 0.2% of flow Common Stock SEC:0001209191-23-011623:0
▼ Chief Accounting Officer · Executives · 17 Feb 2023
4 shares @ US$7.4201 0.7% of flow Common Stock SEC:0001209191-23-011615:0
● Chief Accounting Officer · Executives · 22 Nov 2022
2,521 shares @ US$0.50 30.5% of flow Common Stock SEC:0000899243-22-036999:0
● Director · Executives · 22 Nov 2022
71,363 shares @ US$0.50 100.0% of flow Common Stock SEC:0000899243-22-037001:0
● Chief Financial Officer · Executives · 22 Nov 2022
4,995 shares @ US$0.50 2.7% of flow Common Stock SEC:0000899243-22-037000:0
● Director · Executives · 22 Nov 2022
173,812 shares @ US$0.50 90.1% of flow Common Stock SEC:0000899243-22-036998:0
▼ Chief Accounting Officer · Executives · 17 Nov 2022
86 shares @ US$0.5148 1.1% of flow Common Stock SEC:0000899243-22-036550:0
25 of 56 declarations
Load more (31 remaining) 关于 Eargo, Inc. Eargo, Inc. 是一家在美国纳斯达克市场上市的医疗设备公司,其投资重点是听力健康和面向消费者的医疗技术。该公司成立于2010年,当时名为 Aria Innovations, Inc.,并于2014年更名为 Eargo,总部位于美国加利福尼亚州圣何塞。其定位是专业的听力护理品牌,结合了微型工业设计、易用性和远程客户支持。
Eargo 的核心业务是设计、商业化和销售几乎隐形、可充电、完全入耳式助听器,主要面向患有轻度至中度听力损失的成年人。历史上,该公司一直依赖直销模式,由内部销售顾问、专业的客户服务团队和听力专业人员提供的个性化远程协助支持。这种方法旨在解决传统上限制助听器普及的三个主要障碍:社会耻辱、可及性和成本。
在产品方面,Eargo 专注于助听器的迭代,每一代产品都在音质、舒适度、耐用性、连接性以及佩戴和使用便捷性方面有所改进。最近的发布表明,产品迭代仍然是其战略的核心,包括旗舰设备 Eargo 8 以及增强用户体验的相关应用程序/软件更新。这种节奏在竞争中至关重要,因为 OTC 和高端助听器市场仍然分散,并且对产品设计、客户引导和售后支持高度敏感。
从竞争角度来看,Eargo 处于医疗保健、医疗技术和消费电子的交汇点。其竞争优势不在于规模,而在于产品差异化、品牌形象和远程优先的服务模式。该公司瞄准的是一个渗透率不足的美国市场,对更易获得的听力解决方案的需求仍然具有结构性吸引力。
最近一个值得注意的重点是 Eargo 在2025年继续强调 Eargo 8,并通过产品宣传和外部认可来支持,这突显了管理层努力强化更高端、技术驱动的品牌形象。对于投资者而言,Eargo 仍然是一个利基医疗保健小型股,其业绩取决于商业增长、产品创新以及美国助听器市场演变的执行情况。